Mutations in SMAD4 have been reported to frequently co-exist with KRAS mutations in colorectal cancer [36], and studies in pancreatic cancer suggest that wildtype SMAD4 blocks progression of KRAS G12D-initiated tumors [37]. This evidence concerns the gene KRAS and pancreatic neoplasm.